Peptide receptor-targeted radionuclide therapy of somatostatin receptor-expressing tumors
is a promising application of radiolabeled somatostatin analogs. Suitable radionuclides are …

Imaging somatostatin receptor status with^ sup 68^ Ga labeled peptides has progressed
rapidly over the last several years. It has generated great interest, and stimulated further …

Over the last decade, somatostatin (SST) receptor (R)-positive tumors have been treated
using either^ sup 90^ Y-DOTA-TOC,^ sup 177^ Lu-DOTA-TATE or^ sup 90^ y-DOTA LAN …

Radio-labeled receptor-binding peptides have emerged as an important class of
radiopharmaceuticals. In vertebrates, these peptides transmit their biological function by …

Radiolabeled peptides have been the subject of research for over 20 years and during that
time possibility/variety of peptide receptor imaging and later targeted radiotherapy increased …

The use of radiolabeled peptides for the diagnosis and therapy of cancer has increased
greatly over the last few decades. Skillfully crafted peptide systems, which have high affinity …

There has been an exponential growth in the development of radiolabeled peptides for
diagnostic and therapeutic applications in oncology. Peptides have fast clearance, rapid …

Peptide receptor radionuclide therapy (PRRT) is a very effective treatment modality for
advanced neuroendocrine tumors (NETs), representing a teaching model for truly targeted …

Peptide receptor scintigraphy and peptide receptor radionuclide therapy using radiolabeled
somatostatin receptor (SSTR) agonists are successfully used in the clinic for imaging and …

A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is
the use of radiolabeled somatostatin analogs. Initial studies with high doses of [111 In …